Beena O. Pappen

Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer

John Nemunaitis, Robert O. Dillman, Paul Schwarzenberger et al. · Journal of Clinical Oncology · 2006 · 359 citations · Full text

Medicine, Immunology, Oncology +17

A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors

John Nemunaitis, Alex W. Tong, Michael Nemunaitis et al. · Molecular Therapy · 2009 · 267 citations · Full text

Medicine, Molecular Medicine, Oncology +13

Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer

Neil Senzer, Minal Barve, Joseph A. Kuhn et al. · Molecular Therapy · 2011 · 195 citations · Full text

Medicine, Immunology, Oncology +17

Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients

John Nemunaitis, Michael Nemunaitis, Neil Senzer et al. · Cancer Gene Therapy · 2009 · 146 citations

Medicine, Immunology, Oncology +17

Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer

Minal Barve, James Bender, Neil Senzer et al. · Journal of Clinical Oncology · 2008 · 99 citations

Medicine, Immunology, Oncology +17